Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT

2022 ◽  
Vol 79 (2) ◽  
pp. 220-222
Author(s):  
Nickpreet Singh ◽  
Deepak L. Bhatt ◽  
Michael Miller ◽  
Ph. Gabriel Steg ◽  
Eliot A. Brinton ◽  
...  
Keyword(s):  
Icosapent Ethyl

scholarly journals Risk of Total Events With Icosapent Ethyl

2019 ◽  
Vol 73 (22) ◽  
pp. 2803-2805 ◽  
Author(s):  
Christopher B. Granger ◽  
Adam J. Nelson ◽  
Neha J. Pagidipati
Keyword(s):  
Icosapent Ethyl

scholarly journals PCV55 Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada.

2020 ◽  
Vol 23 ◽  
pp. S496
Author(s):  
J. Lachaine ◽  
J.N. Charron ◽  
J.C. Gregoire ◽  
R.A. Hegele ◽  
L.A. Leiter
Keyword(s):  
Cost Effectiveness ◽  
Cardiovascular Events ◽  
Icosapent Ethyl

REDUCE-IT: outcomes by baseline statin type

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
D Bhatt ◽  
M Miller ◽  
P.G Steg ◽  
E.A Brinton ◽  
T.A Jacobson ◽  
...  
Keyword(s):  
Statin Therapy ◽  
Risk Reduction ◽  
Coronary Revascularization ◽  
Secondary Endpoint ◽  
Nonfatal Stroke ◽  
Funding Source ◽  
Icosapent Ethyl ◽  
Prescription Form ◽  
One Year ◽  
The Impact

Abstract Background REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) randomized 8,179 statin-treated patients with elevated triglycerides and increased cardiovascular (CV) risk to either icosapent ethyl (IPE), a pure, stable prescription form of eicosapentaenoic acid, 4g/day or placebo. IPE significantly reduced time to first occurrence of the primary composite endpoint of major adverse CV events (CV death, nonfatal myocardial infarction [MI], nonfatal stroke, coronary revascularization, or hospitalization for unstable angina) (HR 0.75, CI 0.68–0.83) and key secondary endpoint events (composite of CV death, nonfatal MI, or nonfatal stroke) (HR 0.74, CI 0.65–0.83) versus placebo (all p<0.0001). A modest reduction in placebo-corrected LDL-C was observed (−6.6%; p<0.0001). The mechanisms for the CV benefit of icosapent ethyl are not fully understood. Purpose Explore the impact of statin type and lipophilic/lipophobic category on outcomes, and on LDL-C, to further consider the possible relevance of LDL-C pathways to the observed CV benefit of icosapent ethyl. Methods Primary and key secondary endpoint analyses and LDL-C changes from baseline were explored by individual statin type (atorvastatin, simvastatin, rosuvastatin, or pravastatin) at baseline, and then by categorizing these statins into lipophilic (i.e., hydrophobic: atorvastatin, simvastatin) and lipophobic (i.e., hydrophilic: rosuvastatin, pravastatin) statin groups; 96.1% of patients fell within these individual statin groups. Results CV outcomes were similar across statin types (interaction p=0.61) and lipophilic/lipophobic categories (interaction p=0.51) (Figure). Statin type and category had a similar lack of meaningful impact on the modest placebo-corrected median LDL-C changes from baseline to one year, which ranged from −5.8 to −8.4% (all p≤0.0003). Conclusion No meaningful treatment differences in the primary or key secondary endpoints across statin type or lipophilic/lipophobic category were observed. A similar lack of treatment difference was observed in LDL-C changes from baseline to one year. Therefore, the LDL-C changes and CV risk reduction in REDUCE-IT appear independent of the type of concomitant statin therapy. These data provide clinicians with additional insight regarding concomitant statin therapy considerations when prescribing icosapent ethyl and suggest there are important mechanisms of action for the substantial CV risk reduction observed with icosapent ethyl that are distinct from the LDL receptor pathway. Funding Acknowledgement Type of funding source: Other. Main funding source(s): The study was funded by Amarin Pharma, Inc.

scholarly journals Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials)

2017 ◽  
Vol 119 (3) ◽  
pp. 397-403 ◽  
Author(s):  
Lori Mosca ◽  
Christie M. Ballantyne ◽  
Harold E. Bays ◽  
John R. Guyton ◽  
Sephy Philip ◽  
...  
Keyword(s):  
Eicosapentaenoic Acid ◽  
Ethyl Ester ◽  
Acid Ethyl Ester ◽  
Icosapent Ethyl ◽  
Eicosapentaenoic Acid Ethyl Ester

scholarly journals Icosapent ethyl for the treatment of severe hypertriglyceridemia

2014 ◽  
pp. 485
Author(s):  
Carl J (Chip) Lavie ◽  
Hassan Fares ◽  
James O'Keefe ◽  
James James DiNicolantonio ◽  
Richard Milani
Keyword(s):  
Icosapent Ethyl ◽  
Severe Hypertriglyceridemia

Icosapent Ethyl - More than Just a Fish Tale?

2020 ◽  
Author(s):  
Gregory Curfman ◽  
Emile Shehada
Keyword(s):  
Icosapent Ethyl

Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline

2021 ◽  
pp. 089719002110534
Author(s):  
Jiashan Xu ◽  
Emily Ashjian
Keyword(s):  
Risk Reduction ◽  
Heart Association ◽  
Mesh Term ◽  
Secondary Outcome ◽  
Atherosclerotic Cardiovascular Disease ◽  
Omega 3 ◽  
Individual Agent ◽  
Icosapent Ethyl ◽  
Severe Hypertriglyceridemia ◽  
Ascvd Risk

Background The 2018 American College of Cardiology/American Heart Association (ACC/AHA) guidelines and 2021 ACC Expert Consensus Decision Pathway recommend nonpharmacological interventions and initiation of statin therapy for patients with moderate hypertriglyceridemia and addition of fibrates or omega-3 fatty acids in severe hypertriglyceridemia. Although the association between triglyceride (TG) lowering and atherosclerotic cardiovascular disease (ASCVD) risk reduction remains controversial, patients with hypertriglyceridemia may represent a subgroup that require additional therapy to further reduce residual ASCVD risk. Moreover, medications that target novel pathways could provide alternative options for patients who are intolerant of existing therapies or doses needed to provide adequate triglyceride lowering. Objective: Assess recent evidence for TG-lowering agents including omega-3 fatty acid-based therapies, PPARα modulators, apoC-III mRNA antisense inhibitors, angiopoietin-like 3 (ANGPTL3) antibodies, and herbal supplements. Methods: A literature search was performed using PubMed with hypertriglyceridemia specified as a MeSH term or included in the title or abstract of the article along with each individual agent. For inclusion, trials needed to have a primary or secondary outcome of TG levels or TG lowering. Conclusion: Currently, the only US Food and Drug Administration approved medication for CV risk reduction in patients with hypertriglyceridemia is icosapent ethyl. Results from phase 3 trials for CaPre, pemafibrate, and volanesorsen as well as additional evidence for pipeline pharmacotherapies with novel mechanisms of action (e.g., ApoC-III mRNA antisense inhibitors and ANGPTL3 antibodies) will help to guide future pharmacotherapy considerations for patients with hypertriglyceridemia.

Sign in / Sign up

Export Citation Format

Share Document